| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a robust formulation of aliskiren which has been difficult to formulate and a process suitable for large-scale manufacture of solid oral dosage forms. <P>SOLUTION: The solid oral dosage form, comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and as an additive, a filler, a disintegrant, a lubricant and a glidant, and a binder, is for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure. <P>COPYRIGHT: (C)2013,JPO&INPIT |
